Pathology Disease Articles & Analysis
41 news found
These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
OCT fundus cameras like the Topcon Maestro2 allow us to see a greater detailed image of the eye to find pathology and manage diseases early.” By cross-cutting the retina in a manner similar to an MRI machine, OCT’s high-resolution imaging creates a 3D map of a patient’s eye, enabling doctors to diagnose eye diseases in a single ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners ...
About Biogen As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners ...
Most recently, she was vice president of regional sales for the west at Pathnostics, a diagnostics solutions company specializing in infectious disease and anatomic pathology testing. She has also led sales operations for Pathology Inc., the largest privately-owned women’s health lab on the West Coast. ...
We can and must do more to help people living with MDD and those that care about them overcome the challenges of this disease.” The 11 Sage and Biogen data presentations at Psych Congress were: SHORELINE Study Presentations: Assessing the Need for Repeat Treatment Courses with Zuranolone in Adult Patients With Major Depressive Disorder With Elevated Anxiety: An ...
Mitochondrial dysfunction has been linked to a variety of market therapeutics and pathological diseases. Therefore, studying or maintaining mitochondrial health is paramount to cell health. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical trial, Flamingo-01, has officially started Multiple sites have begun the screening and enrolling process ...
Our goal is to reproduce the Phase IIb clinical trial results, which showed no metastatic breast cancer recurrences in patients treated with GLSI-100 over 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 months.” About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to ...
Digital pathology and cancer informatics provider Inspirata is proud to announce a new partnership with precision pathology company SpIntellx, further strengthening and diversifying Inspirata’s growing partner ecosystem. ...
Chadha is a medical doctor and internationally recognized expert in clinical pathology, neuroscience, neurological disease, and psychiatric disorders. ...
Abstract Number: TPS1110; Poster Number: 485b; Abstract Title: A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 (Co-authored with Baylor College of Medicine) CEO Snehal ...
Harnessing its unique expertise in the microbiome, Axial is developing small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological disorders and disease pathology, progression, and symptoms. The company is advancing a pipeline of “microbial-inspired ...
(Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to ...
ByVaxxinit
About Autism Spectrum Disorder (ASD) According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 44 children has been identified with ASD. ...
Pre-clinical testing shows that MB310 can address key UC disease pathologies, with the ability to repair the epithelial barrier and restore immune homeostasis. ...
” The article, titled “Results and Insights from a Phase 1 Clinical Trial of Lomecel-B for Alzheimer’s disease,” details the study findings on Longeveron’s lead investigational product, Lomecel-B, an allogeneic bone marrow-derived medicinal signaling cell (MSC) product, given to patients with mild Alzheimer’s disease. ...
CY6463 is an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator that is being developed for neurological and neuropsychiatric diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of these disorders. ...
Earlier studies in animal models were the basis for the foundational concept that metabolites produced by intestinal bacteria can circulate in the bloodstream and affect the pathology, progression, and symptoms of neurodegenerative diseases and neurodevelopmental disorders. Axial Therapeutics was founded based on this research as well as additional preclinical ...